Evidence map›Paper›PMID 30617728›Full record

ReviewMolecular imaging and biology2019

A Review of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography (PET) in Renal Cell Carcinoma (RCC).

Thomas Ahn, Matthew J Roberts, Aous Abduljabar, Andre Joshi, Marlon Perera, Handoo Rhee, Simon Wood, Ian Vela

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular imaging and biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
8.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.

  1. Utility of PSMA PET/CT in Staging and Restaging of Renal Cell Carcinoma: A Systematic Review and Metaanalysis.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024
    Pooled it
  2. [European journal of nuclear medicine and molecular imaging · 2026
    Article
  3. Review
  4. Article
  5. Efficacy ofJapanese journal of radiology · 2024
    Article
  6. Article
  7. Characterization ofCancers · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. High Prognostic Value ofDiagnostics (Basel, Switzerland) · 2023
    Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Thomas AhnDepartment of Urology, Greenslopes Private Hospital, Brisbane, Queensland, Australia. thomasahn7@gmail.com.ORCID 0000-0002-2808-9970
Matthew J RobertsDepartment of Urology, Greenslopes Private Hospital, Brisbane, Queensland, Australia.
Aous AbduljabarFaculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
Andre JoshiDepartment of Urology, Townsville Hospital, Brisbane, Queensland, Australia.
Marlon PereraDepartment of Urology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Handoo RheeFaculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
Simon WoodDepartment of Urology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
Ian VelaFaculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
The University of Queensland · AUTranslational Research Institute · AUQueensland University of Technology · AUThe University of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metastatic renal cell carcinoma (mRCC) is a disease that portends poor prognosis despite an increasing number of novel systemic treatment options including new targeted therapies and immunotherapy. Ablative intervention directed at oligometastatic RCC has demonstrated survival benefit. Consequently, developing techniques for improved staging of mRCC on contemporary imaging modalities including X-ray computed tomography (CT), magnetic resonance imaging (MRI) and/or bone scan (BS) is a clinical priority. This is relevant for metastatic deposits too small to characterize or lymph nodes within physiological normality. Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein highly expressed on prostate cancer epithelial cells. Recently, small molecules targeting the PSMA receptor, linked to radioactive isotopes have been developed for use with positron emission tomography (PET). Despite its nomenclature, PSMA has also been found to be expressed in the neovasculature of non-prostate cancers such as renal cell carcinoma (RCC) and hence PSMA PET/CT imaging has been proposed as an alternative staging modality. Preliminary small studies involving the use of PSMA PET/CT imaging in mRCC have been encouraging with evidence of improved staging sensitivity which has directly led to change in management in some cases. Given these early encouraging reports, we performed a comprehensive narrative review on the available evidence, including the scientific basis for PSMA expression in RCC, the role of PSMA PET/CT imaging with potential clinical implications in mRCC, its limitations and future opportunities.

Indexed as

Positron-Emission TomographyCarcinoma, Renal CellHumansKidney NeoplasmsProstate-Specific AntigenProstate-Specific AntigenGalliumMetastasisPositron emission tomographyProstate-specific membrane antigenRenal cell carcinoma

Identifiers

PMID30617728
OpenAlexW2910322053

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.